IP Verse

Solid Compositions Comprising A Glp-1 Agonist And A Salt Of N-(8-(2- Hydroxybenzoyl)Amino)Caprylic Acid

Patent No. EP3326620 (titled "Solid Compositions Comprising A Glp-1 Agonist And A Salt Of N-(8-(2- Hydroxybenzoyl)Amino)Caprylic Acid") was filed by Novo Nordisk on Dec 16, 2011. The application was issued on Mar 4, 2020.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (5)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
GALENICUM HEALTH SLUDec 4, 2020GALENICUM HEALTH SLU
GENERICS UKDec 4, 2020TER MEER STEINMEISTER & PARTNER
HEXALDec 3, 2020MAIWALD
TEVA PHARMACEUTICAL INDUSTRIESDec 1, 2020FACHINI
TEVA PHARMACEUTICALSDec 1, 2020VON KAUFFMANN

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3326620

NOVO NORDISK
Application Number
EP17204363A
Filing Date
Dec 16, 2011
Status
Granted And Under Opposition
Jan 31, 2020
Publication Date
Mar 4, 2020
External Links
Slate, Register , Google Patents